The Biopharma Challenge

Horacio Falcão, Rodrigo Gouveia and Hervé Lamarque
Additional contact information
Horacio Falcão: INSEAD
Rodrigo Gouveia: Value Negotiation

Chapter 4 in Pharma, Prices and Power, 2025, pp 89-137 from Springer

Abstract: Abstract This chapter looks at the second side of P&R negotiations: the biopharma industry. It describes its activities, other players in its ecosystem, revenues, challenges, and how to make it contribute more to the public good. It goes deep into the reasons behind Pharma’s problems and negative reputation, including the tension between health and profit, pricing abuses, negative sales and negotiation tactics, the popular perception of drug prices, and what a correct perception of drug prices would need to incorporate. The readers will gain a tremendous understanding of what really goes on behind the scenes, of the negative tactics used by the industry players, and how that negatively impacts our health. This chapter concludes by discussing what changes are needed so that the industry can deliver much more public good, much more affordably, across its different players instead of the ineffective actions that have been taken so far.

Date: 2025
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:fuobcp:978-3-031-93933-4_4

Ordering information: This item can be ordered from
http://www.springer.com/9783031939334

DOI: 10.1007/978-3-031-93933-4_4

Access Statistics for this chapter

More chapters in Future of Business and Finance from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().